Antitumoral use of cabazitaxel

  • US 10,716,777 B2
  • Filed: 01/15/2020
  • Issued: 07/21/2020
  • Est. Priority Date: 10/29/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method of increasing survival comprising administering to a patient in need thereof a dose of 20 to 25 mg/m2 of cabazitaxel, or a hydrate or solvate thereof, in combination with an H2 antagonist, wherein the H2 antagonist is administered to the patient prior to administering the dose of cabazitaxel, and wherein said patient has castration resistant metastatic prostate cancer that has progressed during or after treatment with docetaxel.

View all claims

    Thank you for your feedback